Vosoritide Patent Expiration
Vosoritide is used for promoting linear growth in pediatric patients with achondroplasia. It was first introduced by Biomarin Pharmaceutical Inc
Vosoritide Patents
Given below is the list of patents protecting Vosoritide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Voxzogo | US10646550 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US11590204 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US11911446 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US9907834 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2036 | Biomarin Pharm |
| Voxzogo | US8198242 | Variants of C-type natriuretic peptide | Jun 11, 2030 | Biomarin Pharm |
| Voxzogo | USRE48267 | Variants of C-type natriuretic peptide | May 20, 2030 | Biomarin Pharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vosoritide's patents.
Latest Legal Activities on Vosoritide's Patents
Given below is the list recent legal activities going on the following patents of Vosoritide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US8198242 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US8198242 |
| Second letter to regulating agency to determine regulatory review period | 05 Jan, 2024 | US8198242 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8198242 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Oct, 2023 | US10646550 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US8198242 |
| Initial letter Re: PTE Application to regulating agency | 03 Aug, 2022 | US8198242 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Sep, 2021 | US9907834 |
| Post Issue Communication - Certificate of Correction | 21 Jan, 2021 | US10646550 |
| Sequence Moved to Public Database | 17 May, 2020 | US10646550 |
Vosoritide's Family Patents
